Cargando…
Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813031/ https://www.ncbi.nlm.nih.gov/pubmed/24250397 |
_version_ | 1782289033163964416 |
---|---|
author | Sistanizad, Mohammad Azizi, Ebrahim Khalili, Hosein Hajiabdolbaghi, Mahboobeh Gholami, Kheirollah Mahjub, Reza |
author_facet | Sistanizad, Mohammad Azizi, Ebrahim Khalili, Hosein Hajiabdolbaghi, Mahboobeh Gholami, Kheirollah Mahjub, Reza |
author_sort | Sistanizad, Mohammad |
collection | PubMed |
description | The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferase-2 phenotype was evaluated by using the chi-square (x(2)) test. The metabolic ratio had a bimodal distribution with an antimode value of 1.0. Based on the metabolic ratio of the mentioned patients, 20 (40%) were slow acetylators and 30 (60%) were fast ones. Hepatotoxicity was manifested in 9 of 20 slow acetylators (45%) and only in 5 of 30 rapid acetylators (16.7%). There was a significant difference in the frequency of hepatotoxicity between the slow and fast acetylators (x(2) = 4.778, and p = 0.03). Sex and age were not found to be risk factors for hepatotoxicity. Our findings show that slow acetylation profile is significantly associated with a higher risk of developing hepatotoxicity due to the anti-TB drugs in Iranian pulmonary tuberculosis patients. |
format | Online Article Text |
id | pubmed-3813031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-38130312013-11-18 Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism Sistanizad, Mohammad Azizi, Ebrahim Khalili, Hosein Hajiabdolbaghi, Mahboobeh Gholami, Kheirollah Mahjub, Reza Iran J Pharm Res Original Article The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferase-2 phenotype was evaluated by using the chi-square (x(2)) test. The metabolic ratio had a bimodal distribution with an antimode value of 1.0. Based on the metabolic ratio of the mentioned patients, 20 (40%) were slow acetylators and 30 (60%) were fast ones. Hepatotoxicity was manifested in 9 of 20 slow acetylators (45%) and only in 5 of 30 rapid acetylators (16.7%). There was a significant difference in the frequency of hepatotoxicity between the slow and fast acetylators (x(2) = 4.778, and p = 0.03). Sex and age were not found to be risk factors for hepatotoxicity. Our findings show that slow acetylation profile is significantly associated with a higher risk of developing hepatotoxicity due to the anti-TB drugs in Iranian pulmonary tuberculosis patients. Shaheed Beheshti University of Medical Sciences 2011 /pmc/articles/PMC3813031/ /pubmed/24250397 Text en © 2011 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services |
spellingShingle | Original Article Sistanizad, Mohammad Azizi, Ebrahim Khalili, Hosein Hajiabdolbaghi, Mahboobeh Gholami, Kheirollah Mahjub, Reza Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title | Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title_full | Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title_fullStr | Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title_full_unstemmed | Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title_short | Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism |
title_sort | antituberculosis drug-induced hepatotoxicity in iraniantuberculosis patients: role of isoniazid metabolic polymorphism |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813031/ https://www.ncbi.nlm.nih.gov/pubmed/24250397 |
work_keys_str_mv | AT sistanizadmohammad antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism AT aziziebrahim antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism AT khalilihosein antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism AT hajiabdolbaghimahboobeh antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism AT gholamikheirollah antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism AT mahjubreza antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism |